Experience of treatment of renal anemia in patients on hemodialysis using epoetin alfa (Eralfon). Evaluation of the efficacy of therapy and comparison with foreign practice


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Purpose. Evaluation of the therapeutic efficacy of the preparation erythropoietin а and the ease of administration of different dosages. Material and methods. The study consisted of two stages. In the beginning, a retrospective study was performed including data of 6О patients who received erythropoietin а in routine practice at the premises of the "Fespharm" Dialysis Center. The purpose of this study was to confirm the hypothesis of small doses of this drug to reach the target Hb level 1ОО-12О g/l. In the subsequent, a prospective study was conducted at the premises of the SBHCI City Clinical Hospital n.a. S.P. Botkin (ЗО patients) in order to evaluate the effectiveness of the use of erythropoietin а for the treatment of renal anemia with doses of the drug, significantly less than the recommended instructions for the drug, and assessing the factors affecting the effectiveness of treatment. Conclusion. With the use of erythropoiesis-stimulating agents (ESA), the authors recommend to take into account the body weight of the patient more strictly, in addition to the absolute total weekly dose of the drug. At the same time, the increase in the ESA dose will be faster than the increase in the patient's body weight. The recommended average doses in the instructions to the drug should be determined taking into account the national characteristics of the population, using preparations with different dosage, be more cautious about the appointment of iron preparations, more focusing on transferrin saturation with iron.

全文:

受限制的访问

作者简介

E. Shutov

SBHCI "CCH n.a. S.P. Botkin of Moscow Healthcare Department"; FSBEI FPE RMACPE

Email: shutov_e_v@mail.ru
Doctor of Medical Sciences, Head of the Department of Nephrology № 12; Professor at the Department of Nephrology and Hemodialysis

O. Kotenko

SBHCI "CCH № 52 of Moscow Healthcare Department"; FSAEI HE PFUR

Email: olkotenko@yandex.ru
PhD in Medical Science, Chief External Expert-Nephrologist of the roscientist of the Moscow Healthcare Department, Deputy Chief Physician for Nephrology; Associate Professor at the Department of Hospital Therapy with the Course of Hematology

A. Pushkina

OOO "Fespharm"

PhD in Medical Sciences, Chief Physician

S. Lashutin

SBHCI "CCH n.a. S.P. Botkin of Moscow Healthcare Department"

Nephrologist

P. Elembaeva

SBHCI "CCH n.a. S.P. Botkin of Moscow Healthcare Department"

Nephrologist

参考

  1. Locatelli F., Aljama P., Bdrdny P., et al. European Best Practice Guidelines Working Group Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol. Dial. Transplant. 2004;19(2):ii1-ii47.
  2. Leaf D.E., Goldfarb D.S. Interpretation and review of health-related quality of life data in CKD patients receiving treatment for anemia. Kidney Int. 2009;75:15-24.
  3. Beusterien K.M., Nissenson A.R., Port F.K., Kelly M.,.Steinwald B., Ware JE. The effects of recombinant human erythropoietin on functional health and well-being in chronic dialysis patients. J. Am.Soc. Nephrol. 1996;7:763- 773.
  4. Справочник ВИДАЛЬ «Лекарственные препараты в России». 2018.
  5. Drueke T.B., Locatelli F., Clyne N., Eckardt K.U., Macdougall I.C., Tsakiris D., Burger H. U., Scherhag A. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N. Engl. J. Med. 2006;355:2071-2084.
  6. Singh A.K., Szczech L., Tang K.L., Barnhart H., Sapp S., Wolfson M., Reddan D: Correction of anemia with epoetin alfa in chronic kidney disease. N. Engl. J. Med. 2006;355:2085-2098.
  7. Земченков А.Ю., Герасимчук Р.П., Костылева Т.Г. и др. Оценка эффективности и безопасности нового отечественного препарата - эритропоэтина альфа. Нефрология и диализ. 2010;12(4):289-296.
  8. Arroyo-Johnson C., Mincey K.D. Obesity epidemiology trends by race/ethnicity, gender, and education: National Health Interview Survey, 1997-2012. Gastroenterol. Clin. North. Am. 2016;45(4):571-579.
  9. Castro A., Skare T.L., Yamauchi F.I., et. al. Diagnostic value of C-reactive protein and the influence ofvisceralfat in patients with obesity and acute appendicitis. Arq. Bras. Cir. Dig. 2018;31(1):e1339.
  10. Tsuriya D., Morita H., Morioka T., et al. Significant correlation between visceral adiposity and high-sensitivity C-reactive protein (hs-CRP) in Japanese subjects. Intern. Med. 2011;50(22):2767-2773.
  11. Charytan D.M., Pai A.B., Chan C.T., Coyne D.W. Considerations and challenges in defining optimal iron utilization in hemodialysis. J. Am. Soc. Nephrol. 2015;26(6):1238-1247.
  12. Khan A., Khan W.M., Ayub M., Humayun M., Haroon M. Ferritin is a marker of inflammation rather than iron deficiency in overweight and obese people. J. Obes. 2016;Epub. 2016 Dec.27.
  13. Ramanathan G., Olynyk J.K., Ferrari P. Diagnosing and preventing iron overload. Hemodial. Int. 2017;58-67.
  14. Yamamoto H., Tsubakihara Y. Limiting iron supplementation for anemia in dialysis patients--the Basis for Japan’s conservative guidelines. Semin. Dial. 2011;24(3):269-271.
  15. Bailie G.R., Larkina M., Goodkin D.A. Data from the Dialysis Outcomes and Practice Patterns Study validate an association between high intravenous iron doses and mortality. J. Kidney Dis., 2015;87(1):162-168.

补充文件

附件文件
动作
1. JATS XML
下载
##common.cookie##